Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

Date publication

août 2023

Journal

Breast cancer (Tokyo, Japan)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Dr BERTAUT Aurélie , Dr COUDERT Bruno , Pr COUTANT Charles , Dr LADOIRE Sylvain , Dr HENNEQUIN Audrey , Dr MAYEUR Didier

Tous les auteurs :
Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Bergeron A, Arnould L, Beltjens F, Desmoulin I, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Amet A, Coutant C, Coudert B, Bertaut A, Ladoire S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37561255

Résumé

Breast cancers without HER2 amplification but still expressing this membrane protein constitute a new entity called HER2-low tumors. It is important to characterize them in terms of sensitivity to treatment and prognosis.

Mots clés

Breast cancer, HER2 low, HER2 zero, Neoadjuvant chemotherapy, Pathologic complete response

Référence

Breast Cancer. 2023 08 10;: